Blood Test Predicts 30-Year Heart Risk

A gloved hand holding a test tube labeled 'Legionella' among other samples

A single blood draw today could forecast your heart attack or stroke risk over the next 30 years, empowering women to act decades before disaster strikes.

Story Highlights

Brigham and Women’s Hospital study tracked 27,939 women for 30 years using three blood biomarkers: hsCRP, LDL-C, and Lp(a).
Women with all three elevated markers faced 2.6 times higher risk of major cardiovascular events and 3.7 times for stroke.
Individual risks: hsCRP 70%, LDL-C 36%, Lp(a) 33% higher—revealing hidden dangers beyond traditional cholesterol checks.
Findings from 1992-1995 Women’s Health Study, published in NEJM September 2024, shift prevention from reactive to proactive.
Available tests now enable early lifestyle changes or meds, potentially slashing events by 30-50% based on precedents.

Study Details from Women’s Health Study

Researchers analyzed blood from 27,939 healthy U.S. women, average age 55, enrolled 1992-1995. They measured high-sensitivity C-reactive protein for inflammation, LDL cholesterol for plaque buildup, and lipoprotein(a), a genetic lipid. Over 30 years, 3,662 suffered major adverse cardiovascular events like heart attacks, strokes, or deaths. Paul M. Ridker led the effort at Brigham and Women’s Hospital, an NIH-funded Harvard affiliate.

Biomarker Risks Quantified Over Decades

Highest hsCRP levels raised cardiovascular event risk 70%, LDL-C 36%, Lp(a) 33%. Women with all three elevated showed 2.6-fold overall MACE risk, jumping to 3.7-fold for stroke. This combo outperforms single markers or traditional scores like Framingham, which ignore inflammation and Lp(a). Genetic Lp(a) affects 20% of people, often undetected until too late. Early detection targets the 50% of heart attacks without prior plaque warnings.

Historical Context and Precedents

Women’s Health Study began in 1992 to track prevention in female health professionals. Past insights include aspirin’s benefits. JUPITER trial in 2008 proved hsCRP-guided statins cut events 44%. Lp(a), discovered 1960s, gained traction in 2020s. Midlife women faced research gaps from male-biased studies pre-1990s. CVD kills one in three women globally, making this U.S.-centric data universally vital.

Recent Confirmations Build Momentum

November 2025 AHA sessions featured UK Biobank data from 300,000 participants over 15 years. Three elevated biomarkers—Lp(a), remnant cholesterol, hsCRP—tripled heart attack risk; two doubled it; one raised it 45%. Vincent Kazibwe noted these tests uncover risks even after controlling traditional factors. NIH endorses early intervention. As of May 2026, no routine combo-test FDA approval, but individual assays exist since 2000s.

Practical Impacts for Midlife Women

Clinicians order hsCRP for $20-50, Lp(a) $50-100 now for ages 45-65. High results prompt statins, PCSK9 inhibitors for Lp(a), or lifestyle shifts, reducing surprises in high-Lp(a) groups. U.S. CVD costs $400 billion yearly; preventing one event saves $100,000. Black women, with higher hsCRP, benefit most from equity focus. AHA/ESC guidelines may standardize by 2027, prioritizing blood tests over costlier imaging.